ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2308건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2210 | Recruiting | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia | COVID-19 | Drug: Azeliragon Drug: Placebo |
Phase 3 | Salim S. Hayek | OTHER | 144 | All | 18 Years | Rush University, Chicago, Illinois, United States University of Michigan, Ann Arbor, Michigan, United States |
| 2209 | Recruiting | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19 | ARDS | Biological: SOC plus 15mg/kg EB05 IV Other: SOC plus Placebo IV |
Phase 3 | Edesa Biotech Inc., JSS Medical Research Inc. | INDUSTRY | 644 | All | 18 Years | UCSF Fresno, Fresno, California, United States St. Jude Medical Center/ Providence, Fullerton, California, United States University of Miami Hospital, Coral Gables, Florida, United States Baystate Medical Center, Springfield, Massachusetts, United States Wayne State University, Detroit, Michigan, United States Providence Portland Medical Center, Portland, Oregon, United States West Virginia University Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States University of Alberta Hospital, Edmonton, Alberta, Canada Vancouver Coastal Health, Vancouver, British Columbia, Canada Vancouver General Hospital, Vancouver, British Columbia, Canada William Osler Health System, Brampton, Ontario, Canada Markham Stouffville Hospital, Markham, Ontario, Canada Southlake Regional Health Centre, Newmarket, Ontario, Canada Lakeridge Health, Oshawa, Ontario, Canada Ottawa Hospital Research Institute, Ottawa, Ontario, Canada Toronto General Hospital, Toronto, Ontario, Canada CISS Monteregie-Centre, Greenfield Park, Quebec, Canada Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada McGill University Health Centre, Montreal, Quebec, Canada Hopital Regional de Rimouski, Rimouski, Quebec, Canada |
| 2208 | Completed | A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19. | Covid19 | Drug: ADX-629 Drug: Placebo |
Phase 2 | Aldeyra Therapeutics, Inc. | INDUSTRY | 11 | All | 18 Years | Medical Research Center of Miami II, Inc., Miami, Florida, United States |
| 2207 | Completed | A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19. | COVID-19 | Biological: HB-adMSCs Other: Placebos |
Phase 2 | Hope Biosciences Stem Cell Research Foundation, Hope Biosciences | OTHER | 53 | All | Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States | |
| 2206 | Terminated | A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 | Coronavirus Disease 2019 (COVID-19) | Biological: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) Biological: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) |
Phase 2 | AstraZeneca | INDUSTRY | 251 | All | 12 Years | Research Site, Birmingham, Alabama, United States Research Site, Modesto, California, United States Research Site, Westminster, California, United States Research Site, Hollywood, Florida, United States Research Site, Lake City, Florida, United States Research Site, Miami Lakes, Florida, United States Research Site, Miami, Florida, United States Research Site, Ormond Beach, Florida, United States Research Site, Wesley Chapel, Florida, United States Research Site, West Palm Beach, Florida, United States Research Site, Chicago, Illinois, United States Research Site, Saint Louis, Missouri, United States Research Site, Knoxville, Tennessee, United States Research Site, Austin, Texas, United States Research Site, El Paso, Texas, United States Research Site, Annandale, Virginia, United States |
| 2205 | Completed | A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine | COVID-19 Vaccine Adverse Reaction | Biological: DNA vaccine OC-007 Other: Placebo |
Phase 1 | Matti Sallberg | OTHER | 16 | All | 18 Years ~ 60 Years | Phase I Study Unit, Karolinska University Hospital, Stockholm, Region Stockholm, Sweden |
| 2204 | Completed | A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) | COVID-19 | Drug: Bamlanivimab | Phase 2 | Eli Lilly and Company, AbCellera Biologics Inc. | INDUSTRY | 109 | All | 12 Years | Presbyterian Medical Center, Albuquerque, New Mexico, United States |
